These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18292291)

  • 1. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.
    Saadoun D; Rosenzwajg M; Landau D; Piette JC; Klatzmann D; Cacoub P
    Blood; 2008 Jun; 111(11):5334-41. PubMed ID: 18292291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naïve B cell apoptosis.
    Holz LE; Yoon JC; Raghuraman S; Moir S; Sneller MC; Rehermann B
    Hepatology; 2012 Nov; 56(5):1602-10. PubMed ID: 22556016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis.
    Mathur P; Emmanuel B; Sneller M; Zhang X; Poonia B; Kottilil S
    J Med Virol; 2018 May; 90(5):936-941. PubMed ID: 29236302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.
    Landau DA; Rosenzwajg M; Saadoun D; Klatzmann D; Cacoub P
    Ann Rheum Dis; 2009 Mar; 68(3):337-44. PubMed ID: 18434450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura.
    Stasi R; Del Poeta G; Stipa E; Evangelista ML; Trawinska MM; Cooper N; Amadori S
    Blood; 2007 Oct; 110(8):2924-30. PubMed ID: 17548576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
    Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D
    Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.
    Roccatello D; Baldovino S; Rossi D; Giachino O; Mansouri M; Naretto C; Di Simone D; Francica S; Cavallo R; Alpa M; Napoli F; Sena LM
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):111-7. PubMed ID: 18270864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
    Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
    Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Delluc A; Piette JC; Cacoub P
    Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab.
    Uppal R; Charles E; Lake-Bakaar G
    J Clin Virol; 2010 Jan; 47(1):69-71. PubMed ID: 19892591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
    Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
    Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
    Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppéré B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P
    Blood; 2010 Jul; 116(3):326-34; quiz 504-5. PubMed ID: 20439619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.
    Sansonno D; De Re V; Lauletta G; Tucci FA; Boiocchi M; Dammacco F
    Blood; 2003 May; 101(10):3818-26. PubMed ID: 12506023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy.
    Quartuccio L; Isola M; Masolini P; Scaini P; Zani R; Tavoni A; Pietrogrande M; Bombardieri S; De Vita S
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S9-14. PubMed ID: 23044040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Twenty-seven years' activities of the French vasculitis study group (FVSG)].
    Guillevin L
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S263-5. PubMed ID: 18029060
    [No Abstract]   [Full Text] [Related]  

  • 17. Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
    Emmanuel B; Sidique N; Zhang X; Poonia B; Sneller MC; Kottilil S
    J Viral Hepat; 2017 Feb; 24(2):128-131. PubMed ID: 27666584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
    Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab.
    Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.
    Terrier B; Saadoun D; Sène D; Sellam J; Pérard L; Coppéré B; Karras A; Blanc F; Buchler M; Plaisier E; Ghillani P; Rosenzwajg M; Cacoub P
    Arthritis Rheum; 2009 Aug; 60(8):2531-40. PubMed ID: 19644879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.